Abstract
San Diego–based Cullgen is the latest start-up launching with plans to develop targeted protein degraders—small molecules that bind a disease-causing protein at one end and tag it for destruction by the cell’s protein-recycling machinery at the other end. The venture capital firms Sequoia Capital China and HighLight Capital together invested $16 million in Cullgen’s series A financing. Cullgen’s initial focus is on cancer, as well as autoimmune and inflammatory diseases.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
